We are a medical technology company focused on changing outcomes for patients. We intend to cure all patients with implant biofilm infections by advancing technologies, enhancing the effectiveness of treatments, working alongside the existing standard of care.
Through partnerships with the University at Buffalo, we have developed treatments and technologies to target and eliminate biofilm infection using low voltage electrochemical disruption. We pride ourselves on innovation and hold multiple patents on our platform technology. In October 2019, we were granted FDA Breakthrough Device designation for our BioPrax™ device and treatment.
In this space, we have garnered global attention and partnerships with several private and public organizations including:
We continue to push the limits of technology in this space and are open to discussing how we can partner together.